Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $6.7 million.

  • Pharmaceuticals' Cash & Equivalents rose 7060177.28% to $6.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.7 million, marking a year-over-year increase of 7060177.28%. This contributed to the annual value of $13.5 million for FY2024, which is 2116.14% down from last year.
  • Latest data reveals that Pharmaceuticals reported Cash & Equivalents of $6.7 million as of Q2 2025, which was up 7060177.28% from $10897.0 recorded in Q1 2025.
  • Pharmaceuticals' 5-year Cash & Equivalents high stood at $47.1 million for Q4 2022, and its period low was $9533.0 during Q2 2024.
  • In the last 5 years, Pharmaceuticals' Cash & Equivalents had a median value of $12.2 million in 2024 and averaged $15.0 million.
  • Over the last 5 years, Pharmaceuticals' Cash & Equivalents had its largest YoY gain of 7060177.28% in 2025, and its largest YoY loss of 9991.07% in 2025.
  • Pharmaceuticals' Cash & Equivalents (Quarter) stood at $38.7 million in 2021, then increased by 21.72% to $47.1 million in 2022, then plummeted by 63.74% to $17.1 million in 2023, then decreased by 21.16% to $13.5 million in 2024, then tumbled by 49.96% to $6.7 million in 2025.
  • Its Cash & Equivalents was $6.7 million in Q2 2025, compared to $10897.0 in Q1 2025 and $13.5 million in Q4 2024.